%0 Journal Article %A TAKAFUMI YAMAMOTO %A NORIHIRO IMAI %A KENTA YAMAMOTO %A TAKANORI ITO %A YOJI ISHIZU %A TAKASHI HONDA %A SHUICHI OKAMOTO %A TAKESHI KANEMATSU %A NOBUAKI SUZUKI %A TADASHI MATSUSHITA %A MASATOSHI ISHIGAMI %A MITSUHIRO FUJISHIRO %T Tolerability of Molecular-targeted Agents for Hepatocellular Carcinoma Treatment in Haemophiliacs %D 2021 %R 10.21873/anticanres.15035 %J Anticancer Research %P 2569-2573 %V 41 %N 5 %X Background: Hepatocellular carcinoma (HCC) is considered a leading cause of death in patients with haemophilia. Recent advances in the treatment of unresectable HCC with molecular-targeted agents (MTAs) have led to better clinical outcomes. However, the tolerability of MTAs by haemophilic patients with HCC remains unclear. Aim: This study aimed to compare the tolerability of MTAs in such patients. Patients and Methods: From January 2011 to October 2020, five haemophilic patients with HCC were treated with MTAs. Adverse events were assessed in comparison with 265 non-haemophilic patients with HCC. Results: The prevalence of hand–foot skin reaction was not higher in the haemophiliacs than in the non-haemophiliacs, whereas the rate of haemorrhagic events was higher in the haemophiliacs (6.0% versus 40.0%, p=0.037). Conclusion: Haemophiliacs tolerate long-term MTA use, without the occurrence of life-threatening complications. However, careful observation and prevention are needed for MTA-related gastrointestinal bleeding in haemophiliacs. %U https://ar.iiarjournals.org/content/anticanres/41/5/2569.full.pdf